[newfocogi]

My (non-AI) Summary:

- "TAR-200 is a miniature, pretzel-shaped drug-device duo containing a chemotherapy drug, gemcitabine, which is inserted into the bladder through a catheter. Once inside the bladder, the TAR-200 slowly and consistently releases the gemcitabine into the organ for three weeks per treatment cycle."

- Phase 2 Clinical Trial

- 85 patients with high-risk non-muscle-invasive bladder cancer

- "treated patients with TAR-200 every three weeks for six months, and then four times a year for the next two years"

- 70/85 patients—the cancer disappeared and still gone 1yr later in almost 50% patients

- FDA granted TAR-200 a New Drug Application Priority Review

- Johnson & Johnson manufactures TAR-200

[woeirua]

Unfortunately the recurrence rate after 1 year here is still quite high. Good progress, but not a cure yet.

[amacbride]

Bladder cancer has a notoriously high recurrence rate, unfortunately. (I worked for years in NMIBC molecular diagnostics.)

[tptacek]

Only a small percentage had a recurrence that progressed to later-stage muscle-invasive illness, though.

[lordofgibbons]

Do cancers have a tendency to come back with better drug resistance if it's not fully eliminated? at least a resistance to the drug that got rid of it the previous time?

[bsder]

This was for a high risk cancer that was already treatment resistant.

This is an unusually effective treatment with remarkably smaller side effects.

If it is this good, it will probably start getting used more broadly.